摘要
背景:蛋白酪氨酸磷酸酶1B(PTP1B)是治疗II型糖尿病和肥胖的重要靶点,因为它在胰岛素和瘦素中起着重要的负性调节作用。点亮道路。 目的:近二十年来,PTP1B抑制剂的发现一直是学术界和制药界研究的热点。 结果与结论:虽然,在这方面强烈的药物研究已经导致许多强有力的PTP1B抑制剂,其中绝大多数具有pTyr模仿组如磷酸盐,钙由于细胞通透性和生物利用度低,导致PTP1B选择性差,体内药效不足。X射线晶体学的有效性PTP1B的结构,以及分子建模和其他创新策略的应用,导致了许多具有理想物理化学性质的PTP1B抑制剂的开发。卡尔属性。本文回顾了PTP1B抑制剂在过去十年的发展,并记录了最近发展起来的新的PTP1B抑制剂,重点是它们的选择性和细胞通透性
关键词: 糖尿病,肥胖,PTP1B抑制剂,分子模型,药物发现,信号通路。
图形摘要
Current Drug Targets
Title:Recent Advances in Protein Tyrosine Phosphatase 1B Targeted Drug Discovery for Type II Diabetes and Obesity
Volume: 19 Issue: 5
关键词: 糖尿病,肥胖,PTP1B抑制剂,分子模型,药物发现,信号通路。
摘要: Background: Protein tyrosine phosphatase 1B (PTP1B) is an important therapeutic target for type II diabetes and obesity because of its pivotal role as a negative modulator in both insulin and leptin signalling pathways.
Objective: The discovery of PTP1B inhibitors has been the focus of researchers in both academia and pharmaceutical industry over the last two decades.
Results and Conclusion: Though, intense pharmaceutical research in this area has resulted in many potent PTP1B inhibitors, a vast majority of them possessed pTyr mimetic group such as phosphonates, carboxylic acids and sulphamic acids, which led to poor PTP1B selectivity and insufficient in vivo efficacy due to low cell permeability and bioavailability. The availability of X-ray crystallographic structures of PTP1B together with the application of molecular modelling and other innovative strategies led to the development of many potent and selective PTP1B inhibitors with desirable physicochemical properties. This review traces the development of PTP1B inhibitors over the last decade and also records novel PTP1B inhibitors developed recently with greater emphasis on their selectivity and cell permeability.
Export Options
About this article
Cite this article as:
Recent Advances in Protein Tyrosine Phosphatase 1B Targeted Drug Discovery for Type II Diabetes and Obesity, Current Drug Targets 2018; 19 (5) . https://dx.doi.org/10.2174/1389450118666170222143739
DOI https://dx.doi.org/10.2174/1389450118666170222143739 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation
Current Vascular Pharmacology Association of Lipoprotein-associated Phospholipase A2 Activity with Components of the Metabolic Syndrome in Apparently Healthy Boys
Cardiovascular & Hematological Agents in Medicinal Chemistry Ultrasonography and Anthropometry for Measuring Regional Body Fat in HIV-Infected Patients
Current HIV Research Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Prediction of Degeneration of Native and Bioprosthetic Aortic Valves:Issue-Related Particularities of Diabetes Mellitus
Infectious Disorders - Drug Targets A Review on the Applications of Nano-medicines in Treatments of Metabolic Diseases
Recent Innovations in Chemical Engineering A Retrospect Study on Thiazole Derivatives as the Potential Antidiabetic Agents in Drug Discovery and Developments
Current Drug Discovery Technologies Molecular Imaging and Targeted Drug Delivery Using Albumin-Based Nanoparticles
Current Pharmaceutical Design Mast Cells as a Double-Edged Sword in Immunity: Their Function in Health and Disease. First of Two Parts
Endocrine, Metabolic & Immune Disorders - Drug Targets Management of Liver Disease in Thalassemia: Main Drug Targets for a Correct Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) Molecular Targets for the Treatment of Multiple Myeloma
Current Cancer Drug Targets Clinical View on the Need to Develop New Anti-Diabetic Drugs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Inhibitors of NAD+ Dependent Histone Deacetylases (Sirtuins)
Current Pharmaceutical Design Metabolic Functions of Myostatin and GDF11
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cefdinir Microsphere Modulated Microflora and Liver Immunological Response to Diet Induced Diabetes in Mice
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-IL-1 β Therapies
Recent Patents on DNA & Gene Sequences MicroRNAs: Biomarkers for Cardiovascular Disease in Patients with Diabetes Mellitus
Current Topics in Medicinal Chemistry Design and Synthesis of Thiazolidinedione Derivates as Selective PPARγ Modulators
Letters in Drug Design & Discovery Have We New Therapeutic Strategies in the Treatment of Renovascular Nephropathy?
Current Vascular Pharmacology